Eli Lilly & Co (LLY) — 10-Q Filings

10-Q Filings (6)

• Eli Lilly's Q3 Revenue Soars 54%, Net Income Jumps 475% — Oct 30, 2025 Risk: medium
  Eli Lilly and Company (LLY) reported a robust financial performance for the quarter ended September 30, 2025, with revenue surging to $17,600.8 million, a signi
• Eli Lilly's Q2 Soars on New Drug Sales, R&D Investment Continues — Aug 7, 2025 Risk: low
  Eli Lilly & Co. reported robust financial performance for the second quarter ended June 30, 2025, driven by strong sales of key pharmaceutical products. Revenue
• Eli Lilly Files Q1 2025 10-Q, Details Debt Maturities — May 1, 2025 Risk: low
  Eli Lilly and Company (LLY) filed its 10-Q for the period ending March 31, 2025. The filing details various financial instruments, including several series of n
• Eli Lilly & Co. Files Q3 2024 10-Q Report — Oct 30, 2024 Risk: medium
  Eli Lilly and Company (LLY) filed its 10-Q for the period ending September 30, 2024. The company reported its financial performance and provided updates on its
• Eli Lilly Files Q2 2024 10-Q, Details Debt — Aug 8, 2024 Risk: low
  Eli Lilly and Company (LLY) filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial performance and position, including v
• Eli Lilly and Company Files 10-Q for Period Ending March 31, 2024 — Apr 30, 2024 Risk: low
  ELI LILLY & Co (LLY) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Eli Lilly and Company filed a 10-Q report for the quarterly period ending M

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX